Increased urinary interleukin 22 binding protein levels correlate with lupus nephritis activity

Journal of Rheumatology

Volumn 41, Issue 9, 2014, Pages 1793-1800

  Yang, Xuyan ^a   Gao, Yin ^a   Wang, Huiying ^a   Zhao, Xiaoying ^a   Gong, Xubo ^a   Wang, Qingqing ^a   Zhang, Xiaofei ^a  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

IL 22 binding protein; Interleukin 22; Lupus nephritis; Renal activity; Systemic lupus erythematosus

Indexed keywords

BIOLOGICAL MARKER; IL22RA2 PROTEIN, HUMAN; INTERLEUKIN DERIVATIVE; INTERLEUKIN RECEPTOR; INTERLEUKIN-22;

ADULT; CROSS-SECTIONAL STUDY; FEMALE; HUMAN; LUPUS NEPHRITIS; MALE; METABOLISM; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; URINE;

ADULT; BIOLOGICAL MARKERS; CROSS-SECTIONAL STUDIES; FEMALE; HUMANS; INTERLEUKINS; LUPUS NEPHRITIS; MALE; MIDDLE AGED; RECEPTORS, INTERLEUKIN; SEVERITY OF ILLNESS INDEX;

EID: 84906854811     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.131292     Document Type: Article

References (37)

1. Eisenberg R. Mechanisms of autoimmunity. Immunol Res 2003;27:203-18.
2. Kotzin BL. Systemic lupus erythematosus. Cell 1996;85:303-6. (Pubitemid 26160701)
3. Dean GS, Tyrrell-Price J, Crawley E, Isenberg DA. Cytokines and systemic lupus erythematosus. Ann Rheum Dis 2000;59:243-51. (Pubitemid 30305564)
4. Chan RW, Lai FM, Li EK, Tam LS, Chow KM, Li PK, et al. Imbalance of Th1/Th2 transcription factors in patients with lupus nephritis. Rheumatology 2006;45:951-7. (Pubitemid 44283048)
5. Sonnenberg GF, Fouser LA, Artis D. Border patrol: regulation of immunity, inflammation and tissue homeostasis at barrier surfaces by IL 22. Nat Immunol 2011;12:383-90.
6. Duhen T, Geiger R, Jarrossay D, Lanzavecchia A, Sallusto F. Production of interleukin-22 but not interleukin-17 by a subset of human skin-homing memory T cells. Nat Immunol 2009;10:857-63.
7. Trifari S, Kaplan CD, Tran EH, Crellin NK, Spits H. Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from T(H)-17, T(H)1 and T(H)2 cells. Nat Immunol 2009;10:864-71.
8. Witte E, Witte K, Warszawska K, Sabat R, Wolk K. Interleukin-22: a cytokine produced by T NK and NKT cell subsets, with importance in the innate immune defense and tissue protection. Cytokine Growth Factor Rev 2010;21:365-79.
9. Sugimoto K, Ogawa A, Mizoguchi E, Shimomura Y, Andoh A, Bhan AK, et al. IL-22 ameliorates intestinal inflammation in a mouse model of ulcerative colitis. J Clin Invest 2008;118:534-44. (Pubitemid 351206544)
10. Pickert G, Neufert C, Leppkes M, Zheng Y, Wittkopf N, Warntjen M, et al. STAT3 links IL-22 signaling in intestinal epithelial cells to mucosal wound healing. J Exp Med 2009;206:1465-72.
11. Zenewicz LA, Yancopoulos GD, Valenzuela DM, Murphy AJ, Stevens S, Flavell RA. Innate and adaptive interleukin-22 protects mice from inflammatory bowel disease. Immunity 2008;29:947-57.
12. Sonnenberg GF, Fouser LA, Artis D. Functional biology of the IL-22-IL-22R pathway in regulating immunity and inflammation at barrier surfaces. Adv Immunol 2010;107:1-29.
13. Ke Y, Sun D, Jiang G, Kaplan HJ, Shao H. IL-22-induced regulatory CD11b+APCs suppress experimental autoimmune uveitis. J Immunol 2011;187:2130-9.
14. Pan HF, Zhao XF, Yuan H, Zhang WH, Li XP, Wang GH, et al. Decreased serum IL-22 levels in patients with systemic lupus erythematosus. Clin Chim Acta 2009;401 Part 1-2:179-80.
15. Yang XY, Wang HY, Zhao XY, Wang LJ, Lv QH, Wang QQ. Th22, but not Th17 might be a good index to predict the tissue involvement of systemic lupus erythematosus. J Clin Immunol 2013;33:767-74.
16. Dumoutier L, Lejeune D, Colau D, Renauld JC. Cloning and characterization of IL-22 binding protein, a natural antagonist of IL-10-related T cell-derived inducible factor/IL-22. J Immunol 2001;166:7090-5. (Pubitemid 32525578)
17. Kotenko SV, Izotova LS, Mirochnitchenko OV, Esterova E, Dickensheets H, Donnelly RP, et al. Identification, cloning, and characterization of a novel soluble receptor that binds IL-22 and neutralizes its activity. J Immunol 2001;166:7096-103. (Pubitemid 32525579)
18. Wei CC, Ho TW, Liang WG, Chen GY, Chang MS. Cloning and characterization of mouse IL-22 binding protein. Genes Immun 2003;4:204-11.
19. Wilson MS, Feng CG, Barber DL, Yarovinsky F, Cheever AW, Sher A, et al. Redundant and pathogenic roles for IL-22 in mycobacterial, protozoan, and helminth infections. J Immunol 2010;184:4378-90.
20. Wolk K, Witte E, Hoffmann U, Doecke WD, Endesfelder S, Asadullah K, et al. IL-22 induces lipopolysaccharide-binding protein in hepatocytes: a potential systemic role of IL-22 in Crohn's disease. J Immunol 2007;178:5973-81. (Pubitemid 46674395)
21. Hochberg M. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997;40:1725-34.
22. Gladman DD, Ibanez D, Urowitz MB. Systemic Lupus Erythematosus Disease Activity Index 2000. J Rheumatol 2002;29:288-91. (Pubitemid 34118775)
23. Bombardier C, Gladman DD, Urowitz MB, Caron D, Chang CH. Derivation of the SLEDAI. Arthritis Rheum 1992;35:630-40.
24. Hernandez-Cruz B, Tapia N, Villa-Romero AR, Reyes E, Cardiel MH. Risk factors associated with mortality in systemic lupus erythematosus. A case-control study in a tertiary care center in Mexico City. Clin Exp Rheumatol 2001;19:395-401. (Pubitemid 32691112)
25. Schiffenbauer J, Simon LS. Randomized controlled trials in systemic lupus erythematosus: what has been done and what do we need to do? Lupus 2004;13:398-405. (Pubitemid 38788503)
26. Petri M, Kasitanon N, Lee SS, Link K, Magder L, Bae SC, et al. Systemic Lupus International Collaborating Clinics renal activity/response exercise: Development of a renal activity score and renal response index. Arthritis Rheum 2008;58:1784-8. (Pubitemid 351847532)
27. Pitashny M, Schwartz N, Qing X, Hojaili B, Aranow C, Mackay M, et al. Urinary lipocalin-2 is associated with renal disease activity in human lupus nephritis. Arthritis Rheum 2007;56:1894-903. (Pubitemid 47110388)
28. Chan TM, Li FK, Tang CS, Wong RW, Fang GX, Ji YL, et al. Efficacy of mycophenolate mofetil in patients with diffuse proliferative lupus nephritis. Hong Kong-Guangzhou Nephrology Study Group. N Engl J Med 2000;343:1156-62.
29. Weening JJ, D'Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int 2004;65:521-30. (Pubitemid 38130646)
30. Grande JP, Balow JE. Renal biopsy in lupus nephritis. Lupus 1998;7:611-17. (Pubitemid 29008227)
31. Piantadosi J, Howlett P, Boland J. Matching the grade correlation coefficient using a copula with maximum disorder. J Ind Manage Optim 2007;3:305-12.
32. Esdaile JM, Joseph L, MacKenzie T, Kashgarian M, Hayslett JP. The benefit of early treatment with immunosuppressive drugs in lupus nephritis. J Rheumatol 1994;21:2046-51. (Pubitemid 24352349)
33. Illei GG, Tackey E, Lapteva L, Lipsky PE. Biomarkers in systemic lupus erythematosus: II. Markers of disease activity. Arthritis Rheum 2004;50:2048-65. (Pubitemid 38924382)
34. Merrill JT, Buyon JP. The role of biomarkers in the assessment of lupus. Best Pract Res Clin Rheumatol 2005;19:709-26. (Pubitemid 41258579)
35. Liu CC, Manzi S, Ahearn JM. Biomarkers for systemic lupus erythematosus: a review and perspective. Curr Opin Rheumatol 2005;17:543-9. (Pubitemid 41527813)
36. Ho A, Magder LS, Barr SG, Petri M. Decreases in anti-double-stranded DNA levels are associated with concurrent flares in patients with systemic lupus erythematosus. Arthritis Rheum 2001;44:2342-9. (Pubitemid 32977502)
37. Karp DR. Complement and systemic lupus erythematosus. Curr Opin Rheumatol 2005;17:538-42. (Pubitemid 41527812)